Flow cytometry analysis revealed an increase in CD8+ T cells within the tumor, and the neutralization of the combination therapy’s enhanced antitumor effect by anti-CD8 monoclonal antibody confirmed the pivotal role of CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.